KHIRON LIFE SCIENCES WKN: A2JMZC ISIN: CA49374L3065 Kürzel: 4KH Forum: Aktien Thema: Hauptdiskussion

Bin mit 3k rein EK 2,30 kein Mumm zum nachkaufen. 🥴

-56% Ich sag ja: nachkaufen!! 😎

-34% bin aber ganz ruhig

-57% wer hat mehr? 🤓

Unter 1 Euro ist echt hart . Khiron war am Anfang noch meine solideste Hanf aktie aber jetzt ist sie das Schlusslicht :( Naja außer wayland natürlich,haha

Aufschwung kommt mit der Legalisierung in Mexiko wenn es den so kommt

2€ minus in 6 Monaten und jetzt fast beim Jahrestief und das am sogenannten “Es fängt erst an” Da würde ich nicht nachkaufen..!! Niemals..🙈🙈🙈 Was fängt an? Nichts .. Es hört auf .,!! Laufe nie 2 x ins gleiche Loch 🕳

Ich glaub, ich kauf mal nach... 👍🏽

Cannabis! Schau dir den Sektor an. Denke, das machst.

Ja, kommt aber wieder. Umsätze sind da und Cash ist auch noch vorhanden. Expansion der Kosmetik Sparte in die USA.

Und ..!! Rums ..

Discussion of operations for three months ended June 30, 2019 The Company recorded a net loss for the three months ended June 30, 2019 of $10.6 million ($0.11 per share) compared to a net loss of $6.2 million for the same period in 2018. Adjusted EBITDA, which excludes mostly non-cash items, was $7.7 million for the three months ended June 30, 2019. Revenues of $2.2 million were recognized from the sale of services at its clinics and sale of its cosmeceutical products, both of which commenced in the fourth quarter of 2018. Revenues were in *** with expectations and gross profits were consistent with the first quarter of 2019. The Company continues to focus on strengthening margins by rebalancing the services of the clinics to focus on higher margin and/or higher volume services. Adjusted EBITDA was a loss of $7.7 million for the second quarter of 2019, which was $2.7 million higher than the prior year second quarter largely due to the growth of the business and readiness to grow in multiple countries. In addition, the Company incurred $1.1 million in research and development costs in the second quarter of 2019 which were related to operating costs at the Company's cultivation site. Management Commentary Alvaro Torres, Khiron CEO and Director, commented: "We are pleased to report significant progress during the Q2 financial reporting period, including revenue generation, expansion of our Kuida cosmeceutical retail network, a growing and more profitable patient base at our ILANS clinics, closing of a $28.75 million bought deal and commencement of full operations at our completed Colombia lab facilities."

Zahlen sind raus.

Cavalier! Wenigstens einer, der es auch versteht ✌️

Wieso sollte es gegen null gehen und welche kriminellen hier geht es doch im nächsten Jahr erst los

Krass, bald unter 1